Sangamo (SGMO) R&D head awarded 225,000 stock options at $0.2601 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sangamo Therapeutics reported that Head of Research & Technology Gregory D. Davis received a new stock option grant. The award covers 225,000 stock options for common shares at an exercise price of $0.2601 per share, expiring on March 31, 2036.

One-quarter of the options will vest on the first anniversary of the grant, with the remaining options vesting in 24 equal monthly installments, contingent on his continued service under the company’s 2018 equity incentive plan. After this grant, he holds 225,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Davis Gregory D

Role Head of Research & Technology

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	225,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 225,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Options Granted: 225,000 options Exercise Price: $0.2601 per share Expiration Date: March 31, 2036 +1 more

4 metrics

Options Granted 225,000 options Stock option award to Gregory D. Davis

Exercise Price $0.2601 per share Strike price for newly granted options

Expiration Date March 31, 2036 Option term end for this grant

Derivative Holdings After Grant 225,000 derivative securities Total options held following this transaction

Key Terms

Stock Option (Right to Buy), exercise price, Continuous Service, 2018 EIP, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "0.2601""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Continuous Service financial

"subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP)"

2018 EIP financial

"subject to acceleration as provided in the 2018 EIP"

vest financial

"shares subject to the option will vest and become exercisable"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Gregory D

(Last)

(First)

(Middle)

C/O SANGAMO THERAPEUTICS, INC.

501 CANAL BLVD.

(Street)

RICHMOND

CALIFORNIA

94804

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Head of Research & Technology

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.2601	04/01/2026		A		225,000		⁽¹⁾	03/31/2036	Common Stock	225,000	$0	225,000	D

Explanation of Responses:

1. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

	/s/ Scott Willoughby, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Sangamo Therapeutics (SGMO) report for Gregory D. Davis?

Sangamo Therapeutics reported that Head of Research & Technology Gregory D. Davis received a grant of 225,000 stock options. These options give him the right to buy common shares at a fixed exercise price if vesting and service conditions are met over time.

How many Sangamo Therapeutics (SGMO) stock options were granted to Gregory D. Davis?

Gregory D. Davis was granted 225,000 stock options linked to Sangamo Therapeutics common stock. Each option represents the right to purchase one share, subject to vesting conditions and an exercise price specified in the equity incentive plan documentation.

What is the exercise price of Gregory D. Davis’s new Sangamo (SGMO) stock options?

The new stock options granted to Gregory D. Davis have an exercise price of $0.2601 per share. This means he can later buy Sangamo common shares at $0.2601 if the options vest and he chooses to exercise before the stated expiration date.

When do the newly granted Sangamo (SGMO) options to Gregory D. Davis expire?

The stock options granted to Gregory D. Davis expire on March 31, 2036. He must satisfy the vesting schedule and exercise the options before that date; otherwise, any unexercised vested options will lapse at expiration under the plan terms.

How do Gregory D. Davis’s Sangamo (SGMO) options vest over time?

One-quarter of the options vest and become exercisable on the first anniversary of the grant date. The remaining options vest in 24 equal monthly installments, contingent on his continuous service under Sangamo’s 2018 Equity Incentive Plan and any acceleration provisions in that plan.

Is Gregory D. Davis’s Sangamo (SGMO) stock option grant an open-market purchase?

No, the transaction is classified as a grant or award acquisition, not an open-market purchase. The Form 4 uses transaction code A for an option grant, reflecting compensation awarded by the company rather than shares bought directly in the market.